TCIM
SIOX

TIAA CREF Investment Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

TIAA CREF Investment Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,161
Closed -$108K – 3138
2018
Q1 		$108K Sell
10,161
-12,730
-56% -$204K ﹤0.01% 3012
2017
Q4 		$965K Buy
22,891
+7,895
+53% +$354K ﹤0.01% 2480
2017
Q3 		$825K Buy
14,996
+4,662
+45% +$786K ﹤0.01% 2616
2017
Q2 		$1.92M Buy
10,334
+2,001
+24% +$351K ﹤0.01% 2210
2017
Q1 		$996K Sell
8,333
-819
-9% -$85.8K ﹤0.01% 2505
2016
Q4 		$909K Sell
9,152
-587
-6% -$61.8K ﹤0.01% 2589
2016
Q3 		$1.09K Buy
9,739
+248
+3% +$29.8K ﹤0.01% 2497
2016
Q2 		$975K Buy
9,491
+4,214
+80% +$421K ﹤0.01% 2520
2016
Q1 		$485K Hold
5,277
– – ﹤0.01% 2794
2015
Q4 		$761K Hold
5,277
– – ﹤0.01% 2737
2015
Q3 		$545K Buy
+5,277
New +$619K ﹤0.01% 2862

Other funds holding SIOX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TIAA CREF Investment Management's SIOX Position: Q2 2018 in Review

TIAA CREF Investment Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2018, closing a stake of 10,161 shares — an estimated $108K sold.

TIAA CREF Investment Management first reported a position in SIOX in Q3 2015 and held it in 11 quarters. The position peaked at $1.92M in Q2 2017. 71 funds tracked by Wall St. Rank hold SIOX as of Q2 2018.

  • TIAA CREF Investment Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • TIAA CREF Investment Management sold 10,161 Sio Gene Therapies Inc. Common Stock shares in Q2 2018, an estimated $108K.
  • TIAA CREF Investment Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 11 quarters.
  • TIAA CREF Investment Management's Sio Gene Therapies Inc. Common Stock position peaked at $1.92M in Q2 2017.
  • 71 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2018.

Based on TIAA CREF Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.